3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
7
Neoplasms
4
Leukemia, B-Cell
3
Recurrence
2
Leukemia
2
Bronchiolitis Obliterans Syndrome
2
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Autoimmune Diseases of the Nervous System
1
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
1
Interventions
Rituximab
67
Cyclophosphamide
39
Vincristine
33
Prednisone
31
Doxorubicin
25
Lenalidomide
18
Radiotherapy
16
Bendamustine Hydrochloride
14
Peripheral Blood Stem Cell Transplantation
10
Filgrastim
10
Etoposide
10
Prednisolone
8
tofacitinib
7
obinutuzumab
6
ibritumomab tiuxetan
6
fludarabine
6
VAP-cyclo protocol
6
Mitoxantrone
6
Methylprednisolone
6
Deoxycholic Acid
6
Cytarabine
6
Melphalan
5
Dexamethasone
5
Carmustine
5
ibrutinib
4
fludarabine phosphate
4
R-CHOP protocol
4
Methotrexate
4
Interferon-alpha
4
Idarubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Follicular
×
ofatumumab
×
Clear all
NCT01077518
2020-03-27
A+B
Novartis
Phase 3
Terminated
346 enrolled
41 charts